Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Multiple myeloma (MM) is a cancer of plasma cells.
• B cell stimulatory factor 2 (BSF-2), also known as interleukin-6 (IL-6), is a key growth factor for myeloma cells.

Purpose of the Study:

• To investigate the correlation between the in vitro response of human myeloma cells to BSF-2 and the clinical characteristics of multiple myeloma patients.
• To evaluate if BSF-2 responsiveness predicts disease progression and chemotherapy response.

Main Methods:

• Human myeloma cells were isolated from 40 patients with IgG multiple myeloma (stages I and III).
• Cells were cultured with recombinant BSF-2 (rBSF-2) for 48 hours.
• 3H-thymidine uptake was measured to assess cell proliferation, and BSF-2 response was quantified by stimulation index and delta counts per minute (cpm).

Main Results:

• Myeloma cells from stage I patients showed a significantly better response to rBSF-2 compared to those from stage III patients.
• Patients whose myeloma cells demonstrated a higher in vitro response to rBSF-2 also exhibited a better response to chemotherapy.
• A correlation was observed between in vitro BSF-2 responsiveness and disease progression.

Conclusions:

• In vitro responsiveness of myeloma cells to BSF-2 is a potential biomarker for multiple myeloma disease progression.
• BSF-2 response in vitro may predict clinical response to chemotherapy in multiple myeloma patients.